A big chunk of Brazilian drugmaker Hypermarcas may be up for grabs—and Big Pharma is all over it.

Investors were in the mood for good news from Eli Lilly—and they got a bit of it in its first-quarter earnings report, even as pipeline worries cast a cloud…

Sanofi has ratcheted up the legal pressure on Mylan with a lawsuit claiming the EpiPen maker abused its monopoly position to “squelch” competition, including…

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Valeant unveiled the sticker on its new psoriasis drug Siliq—and at $3,500 per month it’s the lowest for next-gen meds.

Tesaro has rolled out its ovarian cancer drug Zejula—and unveiled its so-far-secret list price, $9,833 per month. That looks like a discount to AZ's rival…

The whistle continues to blow in a case alleging AstraZeneca defrauded Medicare by playing down the risks of its antipsychotic drug Seroquel, just not as…

Pharma largely continued its price-hiking ways in 2016, and no wonder: The corresponding sales windfall equated to 100% of the industry’s overall earnings-per-…

Biogen's Spinraza raised eyebrows for a $750,000 first-year price, but rare disease medications are expensive, period. Check out this list.

Corporate